We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02494791
Previous Study | Return to List | Next Study

Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer (LS2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02494791
Recruitment Status : Active, not recruiting
First Posted : July 10, 2015
Last Update Posted : May 17, 2022
Sponsor:
Collaborators:
Mount Sinai Hospital, Canada
Sunnybrook Health Sciences Centre
Hamilton Health Sciences Corporation
Ryerson University
University of Toronto
Information provided by (Responsible Party):
University Health Network, Toronto

Brief Summary:
This study will maximize identification of women with Lynch Syndrome using an enhanced screening strategy to identify those at risk. These women will be referred to genetic counselling for testing and those found to have Lynch Syndrome will be asked to invite first degree relatives to participate and undergo genetic testing for Lynch Syndrome. Screening guidelines and risk reducing surgery options for participants found to have Lynch Syndrome will be reinforced by the study and adherence to these guidelines will be assessed annually for ten years following Lynch Syndrome diagnosis to assess the impact and cost-effectiveness of this enhanced screening approach.

Condition or disease Intervention/treatment Phase
Lynch Syndrome Endometrial Neoplasms Ovarian Neoplasms Colorectal Neoplasms Behavioral: Questionnaire, Educational Material Not Applicable

Detailed Description:
Lynch Syndrome increases an individual's risk for several cancers, such as colorectal, endometrial (EC) and certain types of ovarian cancer (OC). Lynch Syndrome is caused by inherited changes in mismatch repair (MMR) genes. In this study we will establish the proportion of EC and OC patients with Lynch Syndrome. We will screen all EC and OC patients by performing MMR immunohistochemistry (IHC) on their surgical specimen. These data will then be used along with family history data to determine which women are at high risk of Lynch Syndrome. We will facilitate the referral of all women at risk for Lynch Syndrome to genetic counselling on behalf of their treating physician. First degree relatives of those patients found to have Lynch Syndrome who consent to participate in the study will also be referred to genetics by the study PI. We will encourage all participants found to have Lynch Syndrome to attend regular colonoscopy screening to prevent colorectal cancer, and (for females with Lynch Syndrome) consideration of gynecologic risk reducing surgery to prevent endometrial and ovarian cancers. We will assess adherence to Lynch Syndrome screening guidelines in this population and will determine if our universal screening strategy is feasible and cost-effective for widespread implementation across Canada in an effort to prevent Lynch Syndrome associated cancers in women and their families. In addition to this, consenting patients may provide blood and tumour tissue samples for sequencing studies which will investigate the genetic basis for Lynch Syndrome and shed light on cases of MMR loss in the absence of germline mutation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 886 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer
Actual Study Start Date : July 2015
Actual Primary Completion Date : July 2020
Estimated Study Completion Date : July 2025


Arm Intervention/treatment
Endometrial and Ovarian Cancer Participants
All study subjects will be offered the same options for screening and follow-up.
Behavioral: Questionnaire, Educational Material
Participants in this study will be given educational material about Lynch Syndrome and genetic testing for this condition. They will be asked to complete questionnaires about their family cancer history, personal health history and attitudes toward genetic testing.




Primary Outcome Measures :
  1. Adherence to screening guidelines (colonoscopy and gynecologic risk-reducing surgery) in participants found to have Lynch Syndrome [ Time Frame: short-term assessment at 1 year after diagnosis, long-term assessment for up to 10 years after diagnosis ]
    Participants found to have Lynch Syndrome will be followed after diagnosis and asked to update the study annually with information about any colorectal cancer screening (colonoscopy) and/or gynecologic risk-reducing surgery they've undergone. This information will be used to assess the success of the enhanced universal screening protocol in helping treat pre-cancerous lesions and therefore prevent a possible cancer as well as aid in detection of early malignancies that otherwise may have gone undetected.

  2. Cost-effectiveness of universal enhanced screening strategy to identify women with Lynch Syndrome and their family members via cascade testing [ Time Frame: short-term assessment at 1 year after diagnosis, long-term assessment for up to 10 years after diagnosis ]
    Data about adherence to screening guidelines and the outcome of screening procedures will be used to inform cost-effectiveness models assessing the feasibility of implementing this enhanced universal screening strategy for Lynch Syndrome in institutions across Canada.


Secondary Outcome Measures :
  1. Incidence of Lynch Syndrome in an unselected group of women with endometrial and non-serous ovarian cancer [ Time Frame: 3 years ]
    This study will add data about the number of Lynch Syndrome cases among a large cohort of endometrial cancer patients in Canada, adding to previous work. This will be the first prospective study to assess Lynch Syndrome incidence in non-serous, non-mucinous ovarian cancer patients in Canada.

  2. Discovery of novel genetic mutations and molecular events in unexplained MMR loss (Lynch-like Syndrome) [ Time Frame: 3-5 years ]
    This study will investigate tumour samples from women with unexplained MMR loss (MMR IHC deficient without a germline mutation) to probe what other factors may contribute to Lynch-like Syndrome. Currently these patients are believed to have an intermediate risk for Lynch-associated cancers and are counselled accordingly. Further investigation into the biology of this condition may yield more effective strategies for stratifying and managing risk for Lynch-like Syndrome patients.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria (Patients):

  • 18-70 years old
  • endometrial cancer (all grades, stages and histologic subtypes except stromal sarcoma, carcinosarcoma)
  • cancer diagnosed within 6 months of consent
  • tumour tissue available for MMR IHC
  • willing and able to give informed consent for participation in study

Exclusion Criteria (Patients):

  • patients under 18 years old or over 70 years old
  • patients with uterine adenosarcoma, leiomyosarcoma or endometrial stromal sarcoma
  • patients with pure serous or pure mucinous ovarian carcinoma
  • patients unwilling or unable to participate in the informed consent process

Inclusion Criteria (First-degree Relatives)

  • minimum 18 years old
  • reside in Canada
  • willing and able to give informed consent for participation in study

Exclusion Criteria (First-degree Relatives):

  • under 18 years old
  • reside outside of Canada
  • unwilling or unable to participate in the informed consent process

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02494791


Locations
Layout table for location information
Canada, Ontario
University Health Network - Princess Margaret Hospital
Toronto, Ontario, Canada, M5T 2M9
Sponsors and Collaborators
University Health Network, Toronto
Mount Sinai Hospital, Canada
Sunnybrook Health Sciences Centre
Hamilton Health Sciences Corporation
Ryerson University
University of Toronto
Investigators
Layout table for investigator information
Principal Investigator: Sarah Ferguson, MD Princess Margaret Cancer Centre
Layout table for additonal information
Responsible Party: University Health Network, Toronto
ClinicalTrials.gov Identifier: NCT02494791    
Other Study ID Numbers: 14-8533CE
First Posted: July 10, 2015    Key Record Dates
Last Update Posted: May 17, 2022
Last Verified: May 2022
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Ovarian Neoplasms
Colorectal Neoplasms
Colorectal Neoplasms, Hereditary Nonpolyposis
Endometrial Neoplasms
Syndrome
Disease
Pathologic Processes
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplastic Syndromes, Hereditary
Genetic Diseases, Inborn
DNA Repair-Deficiency Disorders
Metabolic Diseases
Uterine Neoplasms
Uterine Diseases